PC-SPES: Herbal formulation for prostate cancer

Urology

Volumn 60, Issue 3, 2002, Pages 369-375

  Marks, Leonard S ^a   DiPaola, Robert S ^c   Nelson, Peter ^d   Chen, Sophie ^e   Heber, David ^b   Belldegrun, Arie S ^b   Lowe, Franklin C ^f   Fan, John ^a   Leaders Jr, Floyd E ^g   Pantuck, Allan J ^b   Tyler, Varro E ^h  

^a Urological Sci Research Foundation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f Department of Urology Columbia University School of Medicine ^*  (United States)

^g Botanical Enterprises   (United States)

^h PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN; ANDROGEN RECEPTOR; BAICALIN; DIETHYLSTILBESTROL; ESTROGEN; FLAVONOID; GLYCYRRHIZA EXTRACT; GONADORELIN; LICOCHALCONE A; ORIDONIN; PACLITAXEL; PC SPES; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; SCUTELLARIA BAICALENSIS EXTRACT; VINBLASTINE; WARFARIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLEEDING TENDENCY; CANCER CELL CULTURE; CANCER INHIBITION; CASTRATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ESTROGEN ACTIVITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GYNECOMASTIA; HOT FLUSH; HUMAN; HYPERCOAGULABILITY; IMPOTENCE; LEG CRAMP; LEG SWELLING; LIBIDO DISORDER; NAUSEA; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0036753749     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01913-1     Document Type: Review

References (35)

1. DiPaola R.S., Zhang H., Lambert G.M., et al. Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 339:1998;785-791.
2. Small E.J., Frohlich M.W., Bok R.A., et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 18:2000;3595-3603.
3. Talalay P., Talalay P. The importance of using scientific principles in the development of medicinal agents from plants. Acad Med. 76:2001;238-247.
4. Burton T.M. In trials, potion of herbs slows prostate cancer. 2000;B1. Wall Street Journal, May 17.
5. Wang X., Chen S., Huang H. Anti-cancer pain potency and mechanism of SPES. Raj P., Erdine S., Niv D., et al. Management of Pain A World Perspective . 1996;World Society of Pain Clinic, International Proceedings Division, Lutry, Switzerland.
6. Hsieh T., Chen S.S., Wang X., et al. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int. 42:1997;535-544.
7. Halicka H.D., Ardelt B., Juan G., et al. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC-SPES. Int J Oncol. 11:1997;437-448.
8. Hsieh T., Ng C., Chang C., et al. Induction of apoptosis and down-regulation of BCL-5 in Mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol. 13:1998;1199-1202.
9. Xian W.B. Modern Pharmacology of Chinese Medicine. 1995;Tianjian Scientific Publisher, Beijing.
10. Huang K.C. The Pharmacology of Chinese Herbs. 1993;CRC Press, Boca Raton.
11. Chen S., Ruan Q., Bedner E., et al. Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Prolif. 34:2001;293-304.
12. Oh W.K., George D.J., Hackmann K., et al. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology. 57:2001;122-126.
13. Pfeifer B.L., Pirani J.F., Hamann S.R., et al. PC-SPES, a dietary supplement for the treatment of hormone refractory prostate cancer. BJU Int. 85:2000;481-485.
14. de la Taille A., Buttyan R., Hayek O., et al. Herbal therapy PC-SPES in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer . J Urol. 164:2000;1229-1234.
15. McDonnell T.J., Troncoso P., Brisbay S.M., et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 24:1992;6940-6944.
16. Smith D.C., Redman B.G., Flaherty L.E., et al. A phase II trial of oral DES as a second line hormonal agent in advanced prostate cancer. Urology. 52:1998;257-260.
17. Rafi M.M., Rosen R.T., Vassil A., et al. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 20:2000;2653-2658.
18. Rafi M.M., Vastano B.C., Zhu N., et al. Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J Agric Food Chem. 50:2002;677-684.
19. Weinrobe M.C., Montgomery B. Acquired bleeding diathesis in a patient taking PC-SPES. N Engl J Med. 16:2001;1213-1214.
20. Lock M., Loblaw D.A., Choo R., et al. Disseminated intravascular coagulation and PC-SPES a case report and literature review . Can J Urol. 8:2001;1326-1329.
21. Xing N., Chen Y., Mitchell S.H., et al. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 22:2001;409-414.
22. Huang Y.T., Hwang J.J., Lee P.P., et al. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br J Pharmacol. 128:1999;999-1010.
23. Hasegawa H., Sung J.H., Matsumiya S., et al. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Planta Med. 61:1995;409-413.
24. Matsuzaki Y., Kurokawa N., Terai S., et al. Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Jpn J Cancer Res. 87:1996;170-177.
25. Ghosh D., Wawrzak Z., Pletnev V., et al. Molecular mechanism of inhibition of steroid dehydrogenases by licorice-derived steroid analogs in modulation of steroid receptor function. Ann NY Acad Sci. 761:1995;341-343.
26. Wang S.Y., Hsu M.L., Hsu H.C., et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer. 70:1997;699-705.
27. de la Taille A., Hayek O.R., Buttyan R., et al. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer a preliminary investigation on human cell lines and patients . BJU Int. 84:1999;845-850.
28. Chen S. In vitro mechanism of PC SPES. Urology. 58:(suppl 2A):2001;28-35.
29. Kubota T., Hisatake J., Hisatake Y., et al. PC-SPES a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo . Prostate. 42:2000;163-171.
30. Geliebter J., Mittelman A., Tiwari R.K. PC-SPES and prostate cancer. J Nutr. 131:2001;164S-166S.
31. Hsu S.L., Hsieh Y.C., Hsieh W.C., et al. Baicalein induces a dual growth arrest by modulating multiple cell cycle regulatory molecules. Eur J Pharmacol. 425:2001;165-171.
32. Butenko I.G., Gladtchenko S.V., Galushko S.V. Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from Scutellaria baicalensis georgy roots. Agents Actions. 39:1993;C49-C51.
33. Zava D.T., Blen M., Duwe G. Estrogenic activity of natural and synthetic estrogens in human breast cancer cells in culture. Environ Health Perspect. 105:1997;637-645.
34. Zhai L., Blom J., Chen M., et al. The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob Agents Chemother. 39:1995;2742-2748.
35. Ades T., Gansler T., Miller M., et al. PC-SPES current evidence and remaining questions . CA Cancer J Clin. 51:(3):2001;199-204.